日本特發性肺纖維化治療市場報告（按藥物類別（MAPK 抑制劑、酪胺酸抑制劑、自分泌運動因子抑制劑）、最終用戶（醫院、長期照護機構等）和地區分類）2025 年至 2033 年

2024年，日本特發性肺纖維化治療市場規模達1.81億美元。展望未來， IMARC Group預計到2033年市場規模將達到3.45億美元，2025-2033年期間的成長率（CAGR）為7.4%。

特發性肺纖維化 (IPF) 是一種慢性間質性肺炎，其特徵是肺組織增厚和疤痕形成。 IPF的臨床症狀包括呼吸困難、持續乾咳、疲勞、食慾不振和四肢腫脹。透過血液檢查、胸部X光檢查、電腦斷層掃描 (CT)、肺部活體組織切片和肺功能測試進行診斷。特發性肺纖維化 (IPF) 的治療方法是使用抗纖維化藥物，這種藥物可以減緩疤痕組織的形成速度並控制與疾病相關的症狀。也提供支持性治療方案，包括肺部復健、安寧療護和補充氧氣療法，作為 IPF 的有效治療計劃。

日本特發性肺纖維化治療市場趨勢：

纖維化疾病的盛行率不斷上升，尤其是在老年人群中，這主要推動了日本特發性肺纖維化治療市場的成長。這可以歸因於尼古丁產品消費量的增加、污染水平的激增以及壓力水平的上升。除此之外，健康意識的增強以及對特發性肺纖維化 (IPF) 有效預防和管理策略的認知的提高也是促進成長的因素。其他因素，例如引入新療法的廣泛研究和開發 (R&D) 活動以及現有醫療保健基礎設施的進步，正在對全國市場的成長產生積極影響。

本報告回答的關鍵問題：

• 日本特發性肺纖維化治療市場目前表現如何，未來幾年又會如何表現？
• COVID-19 對日本特發性肺纖維化治療市場有何影響？
• 主要的區域市場有哪些？
• 根據藥品類別，市場是如何分類的？
• 根據最終用戶，市場是如何分類的？
• 該產業的價值鏈分為哪些階段？
• 該行業的主要促進因素和挑戰是什麼？
• 日本特發性肺纖維化治療市場的結構是怎麼樣的？主要參與者有哪些？
• 產業競爭程度如何？

目錄

第1章：前言

第2章：範圍與方法

• 研究目標
• 利害關係人
• 資料來源
  • 主要來源
  • 次要來源
• 市場評估
  • 自下而上的方法
  • 自上而下的方法
• 預測方法

第3章：執行摘要

第4章：簡介

• 概述
• 主要行業趨勢

第5章：日本特發性肺纖維化治療市場

• 市場概覽
• 市場表現
• COVID-19的影響
• 市場預測

第6章：市場區隔：依藥品類別

• MAPK抑制劑
• 酪胺酸抑制劑
• 自分泌運動因子抑制劑

第7章：市場區隔：依最終用戶

• 醫院
• 長期照護機構
• 其他

第 8 章：SWOT 分析

• 概述
• 優勢
• 弱點
• 機會
• 威脅

第9章：價值鏈分析

第 10 章：波特五力分析

• 概述
• 買家的議價能力
• 供應商的議價能力
• 競爭程度
• 新進入者的威脅
• 替代品的威脅

第 11 章：價格分析

第 12 章：政策與監管格局

第 13 章：競爭格局

• 市場結構
• 關鍵參與者
• 關鍵參與者簡介

The Japan idiopathic pulmonary fibrosis treatment market size reached USD 181.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 345.0 Million by 2033, exhibiting a growth rate (CAGR) of 7.4% during 2025-2033.

Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial pneumonia characterized by the thickening and scarring of lung tissue. The clinical symptoms of IPF include breathing difficulties, persistent dry cough, fatigue, loss of appetite, and swollen limbs. It is diagnosed through blood tests, chest X-ray, computer tomography (CT) scan, lung biopsy, and pulmonary function tests. IPF is treated by prescribing anti-fibrotic drugs, which slows the rate at which the scar tissues are formed and controls the symptoms associated with the disease. Supportive therapeutic options, including pulmonary rehabilitation, palliative care, and supplemental oxygen therapy, are also provided as the effective treatment plan for IPF.

Japan Idiopathic Pulmonary Fibrosis Treatment Market Trends:

The increasing prevalence of fibrotic diseases, especially in the geriatric population, is primarily fueling the IPF treatment market growth across Japan. This can be attributed to a rise in the consumption of nicotine-based products, a surge in pollution levels, and rising stress levels. Other than this, increasing health consciousness and rising awareness regarding the effective prevention and management strategies of IPF are acting as growth-inducing factors. Other factors, such as extensive research and development (R&D) activities for introducing novel therapies, and advancements in the existing healthcare infrastructure, are positively influencing the market growth across the country.

Key Market Segmentation:

Breakup by Drug Class:

• MAPK Inhibitors
• Tyrosine Inhibitors
• Autotaxin Inhibitors

Breakup by End User:

• Hospitals
• Long-term Care Facilities
• Others

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Key Questions Answered in This Report:

• How has the Japan idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan idiopathic pulmonary fibrosis treatment market?
• What are the key regional markets?
• What is the breakup of the market based on the drug class?
• What is the breakup of the market based on the end user?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the Japan idiopathic pulmonary fibrosis treatment market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Japan Idiopathic Pulmonary Fibrosis Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 MAPK Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Tyrosine Inhibitors
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Autotaxin Inhibitors
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by End User

• 7.1 Hospitals
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Long-term Care Facilities
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 SWOT Analysis

• 8.1 Overview
• 8.2 Strengths
• 8.3 Weaknesses
• 8.4 Opportunities
• 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

• 10.1 Overview
• 10.2 Bargaining Power of Buyers
• 10.3 Bargaining Power of Suppliers
• 10.4 Degree of Competition
• 10.5 Threat of New Entrants
• 10.6 Threat of Substitutes

11 Price Analysis

12 Policy and Regulatory Landscape

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players

List of Figures

• Figure 1: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
• Figure 2: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019-2024
• Figure 3: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 4: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
• Figure 5: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
• Figure 6: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2024
• Figure 7: Japan: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 8: Japan: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 9: Japan: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 10: Japan: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 11: Japan: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 12: Japan: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 13: Japan: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 14: Japan: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 15: Japan: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 16: Japan: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 17: Japan: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
• Figure 18: Japan: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
• Figure 19: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
• Figure 20: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
• Figure 21: Japan: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2024 and 2033
• Table 2: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
• Table 3: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million USD), 2025-2033
• Table 4: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Competitive Structure
• Table 5: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players